全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Pentamidine Dosage: A Base/Salt Confusion

DOI: 10.1371/journal.pntd.0000225

Full-Text   Cite this paper   Add to My Lib

Abstract:

Pentamidine has a long history in the treatment of human African trypanosomiasis (HAT) and leishmaniasis. Early guidelines on the dosage of pentamidine were based on the base-moiety of the two different formulations available. Confusion on the dosage of pentamidine arose from a different labelling of the two available products, either based on the salt or base moiety available in the preparation. We provide an overview of the various guidelines concerning HAT and leishmaniasis over the past decades and show the confusion in the calculation of the dosage of pentamidine in these guidelines and the subsequent published reports on clinical trials and reviews. At present, only pentamidine isethionate is available, but the advised dosage for HAT and leishmaniasis is (historically) based on the amount of pentamidine base. In the treatment of leishmaniasis this is probably resulting in a subtherapeutic treatment. There is thus a need for a new, more transparent and concise guideline concerning the dosage of pentamidine, at least in the treatment of HAT and leishmaniasis.

References

[1]  World Health Organization (WHO) (1962) WHO Expert Committee on Trypanosomiasis: first report. WHO Technical Report Series, no. 247. Geneva: World Health Organization.
[2]  Food and Agriculture Organization (FAO), World Health Organization (WHO) (1969) African trypanosomiasis: report of a Joint FAO/WHO Expert Committee. WHO Technical Report Series, no. 434. Geneva: World Health Organization.
[3]  World Health Organization (WHO), Food and Agriculture Organization (FAO) (1979) The African trypanosomiases: report of a Joint WHO Expert Committee and FAO Expert Consultation. WHO Technical Report Series, no. 635. Geneva: World Health Organization.
[4]  World Health Organization (WHO) (1986) Epidemiology and control of African trypanosomiasis: report of a WHO Expert Committee. WHO Technical Report Series, no. 739. Geneva: World Health Organization.
[5]  World Health Organization (WHO) (1995) Drugs used in parasitic diseases. Geneva: World Health Organization.
[6]  World Health Organization (WHO) (1998) Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. WHO Technical Report Series, no. 881. Geneva: World Health Organization.
[7]  World Health Organization (WHO) (2003) Report of the Scientific Working Group meeting on African trypanosomiasis. Geneva: World Health Organization.
[8]  Médecins Sans Frontières (2007) Clinical Guidelines. Available through: http://www.refbooks.msf.org/msf_docs/en/?MSFdocMenu_en.pdf. Accessed 22 January 2008.
[9]  Manson-Bahr P (1966) Manson's tropical diseases. London: Baillière, Tindall & Cassell.
[10]  Wilcocks C, Manson-Bahr P (1972) Manson's Tropical Diseases. London: Baillière Tindall.
[11]  Balasegaram M, Harris S, Checchi F, Hamel C, Karunakara U (2006) Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull World Health Organ 84: 777–782. doi: 10.2471/BLT.05.028399
[12]  Eperon G, Schmid C, Loutan L, Chappuis F (2007) Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children. Acta Trop 101: 31–39. doi: 10.1016/j.actatropica.2006.12.002
[13]  World Health Organization (WHO) (1990) Control of the leishmaniases: report of a WHO Expert Committee. WHO Technical Report Series, no. 793. Geneva: World Health Organization.
[14]  World Health Organization (WHO) (1984) The leishmaniases: report of a WHO Expert Committee. WHO Technical Report Series, no. 701. Geneva: World Health Organization.
[15]  Bryceson A (1987) Therapy in man. In: Peters W, Killick-Kendrick R, editors. The leishmaniases in biology and medicine. Volume II: clinical aspects and control. London: Academic Press. pp. 847–907.
[16]  Delobel P, Pradinaud R (2003) Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J Antimicrob Chemother 51: 1319–1320. doi: 10.1093/jac/dkg195
[17]  Jha SN, Singh NK, Jha TK (1991) Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 39: 314–316.
[18]  Budavari S (1996) The Merck Index. Whitehouse Station (New Jersey): Merck & Co.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133